Wed, Mar 5, 7:17 PM (53 days ago)
**Summary of OrthoPediatrics Corp. (Ticker: KIDS) 2024 10-K Report** OrthoPediatrics Corp. reported a significant revenue increase of 38% to $204.7 million in 2024, driven by strong sales in trauma and deformity, scoliosis, and the acquisition of Boston O&P. The company incurred a net loss of $37.8 million, exacerbated by rising costs in sales and marketing (22% increase) and general administrative expenses (40% increase). Gross margin slightly declined to 73% from 75%, reflecting the impact of acquisitions. The company’s total assets reached $473.2 million, with liabilities of $118.6 million, including $24 million in long-term debt. As of December 31, 2024, OrthoPediatrics had a cash balance of $45.8 million and an accumulated deficit of $235.6 million. The firm continues to expand its product offerings and international presence, focusing on pediatric orthopedic solutions. Key risks include reliance on third-party sales networks, regulatory compliance, and potential impacts from health crises like RSV and COVID-19. The company’s strategic initiatives aim to enhance market penetration and operational efficiency while navigating a competitive landscape. Future outlook remains cautious, with ongoing investments in R&D and infrastructure to support growth.